Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC.
J Natl Cancer Inst. 2022 Jan 30:djac015. doi: 10.1093/jnci/djac015. Online ahead of print.
J Natl Cancer Inst. 2022.
PMID: 35094066